Debra Foster, BSc, began her professional career as a registered nurse, specializing in the adult critical care area. Shortly thereafter, Debra joined the critical care clinical research team at Toronto General Hospital. While there, Debra was the project lead for a multi-national, multi-center clinical trial, the MEDIC study. The data was used for a successful 510k de novo submission to the FDA for the Endotoxin Activity Assay (EAA). It was the first in vitro disagnostic (IVD) in the field of sepsis. Debra followed the device to its commercial partner, becoming an employee of Spectral Medical. She was appointed Vice President of Clinical Development in 2011. Debra has led many clinical research projects, including the EUPHRATES and TIGRIS clinical trials for a device to treat patients with endotoxemic septic shock. In December 2021, Debra opted for partial retirement and remains a clinical consultant for Spectral Medical.

Debra has lectured many times to medical professionals on the topics of sepsis and clinical trials for sepsis. She has co-authored more than 50 articles in peer-reviewed journals and lectured for academic and industry audiences. 

Session Title: Spectral Medical Sponsored Session: What is Endotoxin and Why is it Important?

Session Day/Time: Wednesday, September 27, 2023, 1:40 - 2:10 PM EST

Access Session